The Albus Program is an annual international award focused on innovative ideas related to albumin and its role as a therapeutic product. Proposals may include, but are not limited to: efficacy, mechanism of action, safety and tolerability, quality of life and pharmacoeconomics.

The Program offers 1 award of €50,000 to applicants whose proposals best match the program’s objectives, as assessed by an independent review committee. Albus aims to:

• Develop novel concepts on albumin research.
• Encourage discovery of beneficial albumin applications.
• Further investigate mechanisms of action or clinical effects in different indications.